ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NAS: IMGN) , a biotechnology company that develops anticancer therapeutics, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Company's analyst and investor community meeting on April 12, 2013. The webcast will begin at 8:30 a.m. ET and may be accessed through the Investor Information section of the Company's website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company's website through April 26, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, KadcylaTM (formerly T-DM1) has been approved for marketing in the US and is undergoing regulatory review in Europe and Japan; it is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
KEYWORDS: United States North America Massachusetts
The article ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.